Wave Life Sciences (WVE) director’s 432-share tax-cover sale under 10b5-1 plan

Rhea-AI Filing Summary

Wave Life Sciences, Inc. director Tan Aik Na reported a small open-market sale of 432 shares of common stock on August 11, 2026 at $6.01 per share. According to the disclosure, the shares were sold solely to cover taxes from vesting restricted stock units on the same date, under a previously adopted Rule 10b5-1 Trading Plan. Following this transaction, the director directly holds 24,968 shares of Wave Life Sciences, Inc. common stock.

Insider Trade Summary 10b5-1

Net Seller: 432 shares

Net Sell 1 txn

Insider Tan Aik Na

Role Director

Sold 432 shs ($3K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	432	$6.01	$3K

Holdings After Transaction: Common Stock — 24,968 shares (Direct)

Footnotes (1)

1. F1. On August 11, 2026, the reporting person sold 432 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.

Key Figures

Shares sold: 432 shares Sale price per share: $6.01 per share Shares owned after transaction: 24,968 shares +3 more

6 metrics

Shares sold 432 shares Common stock sale on August 11, 2026

Sale price per share $6.01 per share Price received for 432 shares sold on August 11, 2026

Shares owned after transaction 24,968 shares Direct holdings following the August 11, 2026 sale

Net shares sold 432 shares Net sell volume across all reported transactions in this Form 4

Transaction date August 11, 2026 Date of RSU vesting and related tax-cover sale

Redomiciliation exchange ratio 1-for-1 One Wave-Singapore ordinary share for one Wave Life Sciences, Inc. common share

Key Terms

Rule 10b5-1 Trading Plan, restricted stock units, Redomiciliation, scheme of arrangement

4 terms

Rule 10b5-1 Trading Plan financial

"These sales were made pursuant to a previously adopted 10b5-1 Trading Plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"sold 432 shares of common stock solely to cover taxes associated with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Redomiciliation regulatory

"The Redomiciliation had the effect of changing Wave-Singapore's domicile"

Redomiciliation is when a company legally changes its country of incorporation while keeping the same business and assets, like moving a house to a new neighborhood but keeping the same furniture. Investors care because the company then follows a different set of laws and tax rules, which can change shareholder rights, reporting standards, dividend treatment and the ease of trading the stock, potentially affecting risk and return.

scheme of arrangement regulatory

"pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares"

A scheme of arrangement is a legal agreement between a company and its shareholders or creditors to reorganize or settle debts, often to avoid bankruptcy or make big changes. It’s like a carefully planned handshake that everyone agrees to, helping the company stay afloat or improve its financial health.

FAQ

What did Tan Aik Na report in the Form 4 for Wave Life Sciences (WVE)?

Tan Aik Na reported selling 432 shares of Wave Life Sciences, Inc. common stock on August 11, 2026 at $6.01 per share. The filing states the sale was solely to cover taxes from vesting restricted stock units under a pre-arranged Rule 10b5-1 plan.

How many Wave Life Sciences (WVE) shares does Tan Aik Na hold after this transaction?

After the reported sale, Tan Aik Na directly holds 24,968 shares of Wave Life Sciences, Inc. common stock. This remaining position is disclosed as the total direct ownership following the 432-share tax-cover sale on August 11, 2026.

Was the Wave Life Sciences (WVE) Form 4 sale made under a Rule 10b5-1 plan?

Yes. The filing states the 432-share sale on August 11, 2026 was made pursuant to a previously adopted Rule 10b5-1 Trading Plan. Such plans pre-arrange trades, reducing the informational value of the transaction’s timing for investors.

What was the purpose of the Wave Life Sciences (WVE) share sale reported by Tan Aik Na?

The Form 4 explains that the 432 shares of common stock were sold solely to cover taxes related to the vesting of restricted stock units on August 11, 2026. This indicates a tax-related transaction rather than a discretionary portfolio rebalancing sale.

What price was received for the Wave Life Sciences (WVE) shares sold in this Form 4?

The reported sale price was $6.01 per share for 432 shares of Wave Life Sciences, Inc. common stock on August 11, 2026. The transaction is described as a sale in the open market or private transaction, as coded in the Form 4.

Does the Wave Life Sciences (WVE) Form 4 mention any change in shareholder proportions from the redomiciliation?

The remarks explain that a prior redomiciliation from Wave Life Sciences Ltd. (Singapore) to Wave Life Sciences, Inc. (Delaware) did not alter proportionate securityholder interests. All Singapore ordinary shares were exchanged one-for-one for Delaware common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/13/2026 - 09:00 PM Accepted by SEC EDGAR 08/13/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tan Aik Na

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES, INC.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences, Inc. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		S(1)		432	D	$6.01	24,968	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On August 11, 2026, the reporting person sold 432 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.

Remarks:

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney

	/s/ Aik Na Tan	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)